Prothena Corporation plc (PRTA)

Prothena Corporation plc is a clinical-stage biotechnology company focused on developing novel therapies for diseases caused by protein misfolding and amyloidosis. Founded in 2012, the company is headquartered in Dublin, Ireland, with operations in the United States. Prothena is committed to advancing the science behind neurodegenerative disorders and other related conditions, with a robust pipeline that includes treatments for Alzheimer's disease, Parkinson's disease, and ATTR amyloidosis. As of the most recent update, the CEO of Prothena is Gene Kinney, who is also the President and a member of the company's Board of Directors. Prothena's innovative research and development efforts are primarily targeted towards leveraging their expertise in protein dysregulation to discover and develop precision therapies. While specific revenue figures can fluctuate yearly due to the nature of biotech R&D and partnerships, Prothena commonly collaborates with other industry leaders to enhance their development programs.